UMBI has many technologies available for licensing:

A novel approach for the early diagnosis of prostate cancer

Regulating programmed cell death by activating the autophagic pathway

A Salmonella-based oral vaccine for Anthrax

Prion diseases: In vitro conversion assay and applications

Antibacterial agent production from marine bacteria, Silicibacter

Surface layer coated biodegradable microcapsules for oral drug delivery

Ultra-fast, highly sensitive Metal-enhanced Chemiluminescence (MEC)

Highly sensitive fluorescence microwave microscope

Novel imaging agents to measure the in vivo concentration of oxygen in the brain using Electron Paramagnetic Resonance (EPR) imaging

Generation, characterization and isolation of primary human antibody in vitro

Targets for eliminating misfolded proteins that cause human disease (e.g. neurodegenerative diseases)

Recombinant protein expression using protozoan organisms

Antibody assembly on chitosan nanofibers

Zero discharge re-circulated marine aquaculture system and bio-filters to control ammonia levels

Novel Therapy for Herpes Virus Infections

UMBI also offers fee for service programs

If you would like additional information on any of the above technologies, to view additional technologies available here at UMBI, or wish to discuss licensing/option terms, please contact:

Jonathan Gottlieb, Ph.D., MBA
Director, Technology Transfer and Commercialization
UMBI Research, Innovation & Commercialization
701 East Pratt Street
Suite 200, Central Administration
Baltimore, Maryland 21202
(240) 314-6506
(410) 385-6331 (f)
gottlieb@umbi.umd.edu